Marvel Biosciences Corp. (MRVL.V)
CAD 0.16
(10.34%)
CAD 0.16
(10.34%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.31 Million CAD | 11.48% |
| 2022 | -2.54 Million CAD | -415.5% |
| 2021 | 806.33 Thousand CAD | 184.5% |
| 2020 | -954.2 Thousand CAD | -853.72% |
| 2019 | -100.05 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -237.74 Thousand CAD | 5.66% |
| 2024 Q2 | -252 Thousand CAD | 42.69% |
| 2024 Q1 | -439.74 Thousand CAD | 57.57% |
| 2023 Q2 | -230.48 Thousand CAD | 18.56% |
| 2023 FY | -2.25 Million CAD | 11.48% |
| 2023 Q3 | -692.84 Thousand CAD | -200.6% |
| 2023 Q4 | -1.03 Million CAD | -49.6% |
| 2023 Q1 | -283.03 Thousand CAD | 51.37% |
| 2022 Q1 | -509.94 Thousand CAD | -134.89% |
| 2022 FY | -2.54 Million CAD | -415.5% |
| 2022 Q4 | -582 Thousand CAD | -49.7% |
| 2022 Q2 | -1.06 Million CAD | -108.5% |
| 2022 Q3 | -388.79 Thousand CAD | 63.43% |
| 2021 Q2 | -172.06 Thousand CAD | 52.93% |
| 2021 Q1 | -365.55 Thousand CAD | 0.0% |
| 2021 FY | 806.33 Thousand CAD | 184.5% |
| 2021 Q3 | -253.68 Thousand CAD | -47.44% |
| 2021 Q4 | 1.46 Million CAD | 676.05% |
| 2020 FY | -954.2 Thousand CAD | -853.72% |
| 2019 FY | -100.05 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.35 Million CAD | 30.885% |
| Covalon Technologies Ltd. | -4.48 Million CAD | 48.343% |
| Hemostemix Inc. | -2.33 Million CAD | 0.626% |
| Universal Ibogaine Inc. | 497.15 Thousand CAD | 566.444% |
| Kane Biotech Inc. | -3.35 Million CAD | 30.93% |
| MedMira Inc. | -1.94 Million CAD | -19.267% |
| NervGen Pharma Corp. | -17.77 Million CAD | 86.955% |
| XORTX Therapeutics Inc. | -6.38 Million CAD | 63.664% |